Show Notes
Protectors from hospitalisation, the story so far.Oral meds than can be prescribed from home with onset of symptomsUploaded 07-11-21Molnupiravir, approved by MHRAhttps://www.gov.uk/government/news/first-oral-antiviral-for-covid-19-lagevrio-molnupiravir-approved-by-mhraThe antiviral was found to be safe and effective following a stringent review of the available evidence.https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/Public domain data, Merck press release$ 700 per 5-day courseUnder 50% reduction in deuteriationEffect of early treatment with fluvoxamineTogether Trial groupPublic domain data, Peer reviewed trial in the Lancethttps://clinicaltrials.gov/ct2/show/NCT04727424https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(21)00448-4/fulltextAdults with a risk factor$4 for a 10-day course32% protection against hospitalization32% protection against deathFluvoxamine is approved by the Food and Drug Administration as an antidepressantDoctors already can prescribe it off-label — using their clinical judgmenthttps://www.washingtonpost.com/science/2021/10/28/antidepressant-fluvoxamine-coronavirus-lancet/?https://bnf.nice.org.uk/drug/fluvoxamine-maleate.htmlhttps://www.togethertrial.comIvermectin, Together trial results not yet releasedPFIZER’S NOVEL COVID-19 ORAL ANTIVIRAL TREATMENT CANDIDATE REDUCED RISK OF HOSPITALIZATION OR DEATH BY 89% IN INTERIM ANALYSIS OF PHASE 2/3 EPIC-HR STUDYhttps://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidatePublic domain data, Pfizer press releasePAXLOVID™ (PF-07321332; ritonavir)Found to reduce the risk of hospitalization or death by 89% Compared to placebo in non-hospitalized high-risk adults with COVID-19Through Day 28PAXLOVID groupNo deathsPlacebo group10 deathsPfizer plans to submit the data as part of its ongoing rolling submission to the U.S. FDA for Emergency Use Authorization (EUA) as soon as possiblePhase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) Randomized, double-blind study of non-hospitalized adult patients with COVID-19, who are at high risk of progressing to severe illness Scheduled interim analysis89% reduction in risk of COVID-19-related hospitalization or death from any cause compared to placeboIn patients treated within 3 days of symptom onsetPAXLOVID group0.8% of patients hospitalized3/389 hospitalized with no deathsPlacebo group7.0% of patients hospitalized or died27/385 hospitalizedwith 7 subsequent deaths(p less than 0.0001) 1 in 10,000 chanceIn patients treated within 5 days of symptom onsetPAXLOVID group1.0% of patients hospitalized6/607 hospitalized with no deathsPlacebo group6. 7% of patients hospitalized or died41/612 hospitalized,with 10 subsequent deathsp less than 0.0001At the recommendation of an independent Data Monitoring Committee and in consultation with the U.S. Food and Drug Administration (FDA), Pfizer will cease further enrollment into the studydue to the overwhelming efficacy demonstrated in these resultsAbout the Phase 2/3 EPIC-HR Study Interim Analysis1,219 adults enrolled out of 3,000 plannedNorth and South America, Europe, Africa, and AsiaEnrolled individuals had a laboratory-confirmed diagnosis of SARS-CoV-2 infectionMild to moderate symptomsAt least one characteristic or underlying medical conditionRandomized (1:1) to receive PAXLOVID™ or placebo orally every 12 hours for five daysAbout the Phase 2/3 EPIC-HR Study Safety DataSafety data, n = 1881Treatment-emergent adverse eventsPAXLOVID™group 19%Placebo group21%Most of which Learn more about your ad choices. Visit megaphone.fm/adchoices
More from Dr. John Campbell
Free downloads of my books, https://drjohncampbell.co.uk/ Uploaded 27-02-25Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices
Professor David Nutt, doctor, psychiatrist, neuropsychopharmacologist, addiction specialist, medical author and researcher. Leading expert on brain chemistry, the effects of alcohol, and the GABA system.Uploaded 13-05-25Link for Sentia drinks, https://sentiaspirits.com/David founded SENTIA Spirits to achieve his vision of bringing safer, better choices to adult social drinkers.Link for Drink? UK link, https://www.amazon.co.uk/Drink-Science-Alcohol-Your-Health/dp/B07YX52JLR/ref=sr_1_1?crid=2CICWKTQ2JV3G&dib=eyJ2IjoiMSJ9.aJAoDtBh4cjOSqJe7adChK_tZ8CwQp9YPQgbUer7xKcLmQkqz0biMtFM8Y3SUkzDruAr8hJg8aYyAswq90VrTNa58iL58pFzQJncYJqifnXS3KB0vvalvEqbygogaLqs.G0fMPUA2osO5moD_aY8Vzk9joOSu5dyDJl-Vhk9EdYc&dib_tag=se&keywords=drink+david+nutt&qid=1747172137&sprefix=drink+david+nutt%2Caps%2C91&sr=8-1US link, https://www.amazon.com/Drink-New-Science-Alcohol-Health/dp/030692384X/ref=sr_1_1?crid=3JE2731TAQ8JO&dib=eyJ2IjoiMSJ9.mwR5QFRJgtmJUODgz0GYy90h23yRviakZe71yl9_qLDGjHj071QN20LucGBJIEps.3Y7Z7ETTPt0FcJL_3WHhXDz5YJUe9HAp3qA3pzkdYoM&dib_tag=se&keywords=drink+david+nutt&qid=1747172435&sprefix=drink+david+nutt%2Caps%2C176&sr=8-1 Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices
Massive APPARENT reduction in excess deaths in 2023 as UK ONS change how they calculate excess deaths.
Professor David Nutt, doctor, psychiatrist, neuropsychopharmacologist, addiction specialist, medical author and researcher. Leading expert on brain chemistry, the effects of alcohol, and the GABA system.Uploaded 03-06-25This video is a clip from this full interview, https://studio.youtube.com/video/ocSPQp49DtQ/editLink for Sentia drinks, https://sentiaspirits.com/David founded SENTIA Spirits to achieve his vision of bringing safer, better choices to adult social drinkers.Link for Drink? UK link, https://www.amazon.co.uk/Drink-Science-Alcohol-Your-Health/dp/B07YX52JLR/ref=sr_1_1?crid=2CICWKTQ2JV3G&dib=eyJ2IjoiMSJ9.aJAoDtBh4cjOSqJe7adChK_tZ8CwQp9YPQgbUer7xKcLmQkqz0biMtFM8Y3SUkzDruAr8hJg8aYyAswq90VrTNa58iL58pFzQJncYJqifnXS3KB0vvalvEqbygogaLqs.G0fMPUA2osO5moD_aY8Vzk9joOSu5dyDJl-Vhk9EdYc&dib_tag=se&keywords=drink+david+nutt&qid=1747172137&sprefix=drink+david+nutt%2Caps%2C91&sr=8-1US link, https://www.amazon.com/Drink-New-Science-Alcohol-Health/dp/030692384X/ref=sr_1_1?crid=3JE2731TAQ8JO&dib=eyJ2IjoiMSJ9.mwR5QFRJgtmJUODgz0GYy90h23yRviakZe71yl9_qLDGjHj071QN20LucGBJIEps.3Y7Z7ETTPt0FcJL_3WHhXDz5YJUe9HAp3qA3pzkdYoM&dib_tag=se&keywords=drink+david+nutt&qid=1747172435&sprefix=drink+david+nutt%2Caps%2C176&sr=8-1 Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices
Dr. David Grimes, consultant physician gives amazing information on the importance of immunity and vitamin D. Buy his inexpensive latest book here. https://yorkbookshop.com/health-and-personal-development/307-vitamin-d-deficiency-and-covid-19-its-central-role-in-a-world-pandemic.html Uploaded 15-01-24Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices